	US 12,343,400 B2
	Brain tumor-targeting peptide and application thereof
Jian Lin, Jiangsu (CN); Long Chen, Jiangsu (CN); Chengpeng Li, Jiangsu (CN); and Chaogang Li, Jiangsu (CN)
Assigned to JIANGSU JITRI MOLECULAR ENGINEERING INST. CO., LTD., Jiangsu (CN)
Appl. No. 17/295,566
Filed by JIANGSU JITRI MOLECULAR ENGINEERING INST. CO., LTD., Jiangsu (CN)
PCT Filed Jan. 17, 2020, PCT No. PCT/CN2020/072652 § 371(c)(1), (2) Date Oct. 14, 2021, PCT Pub. No. WO2020/103961, PCT Pub. Date May 28, 2020.
Claims priority of application No. 201811392953.1 (CN), filed on Nov. 21, 2018.
Prior Publication US 2022/0331440 A1, Oct. 20, 2022
Int. Cl. A61K 47/64 (2017.01); A61K 31/337 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01)

CPC A61K 47/64 (2017.08) [A61K 31/337 (2013.01); A61P 35/00 (2018.01)]

15 Claims

1. A brain tumor targeted molecule, comprising a blood-brain barrier crossing region and a tumor target region, wherein the blood-brain barrier crossing region comprises SEQ ID NO: 1.